Brave Asset Management Inc. Has $648,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Brave Asset Management Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 6.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,418 shares of the biopharmaceutical company’s stock after selling 1,767 shares during the period. Brave Asset Management Inc.’s holdings in Pfizer were worth $648,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Lmcg Investments LLC grew its position in Pfizer by 1.1% during the second quarter. Lmcg Investments LLC now owns 51,777 shares of the biopharmaceutical company’s stock worth $1,449,000 after buying an additional 543 shares in the last quarter. Pekin Hardy Strauss Inc. raised its stake in shares of Pfizer by 8.4% in the second quarter. Pekin Hardy Strauss Inc. now owns 27,095 shares of the biopharmaceutical company’s stock valued at $758,000 after purchasing an additional 2,090 shares in the last quarter. Edgestream Partners L.P. boosted its stake in Pfizer by 1,704.3% during the second quarter. Edgestream Partners L.P. now owns 157,967 shares of the biopharmaceutical company’s stock worth $4,420,000 after buying an additional 149,212 shares in the last quarter. Perennial Investment Advisors LLC lifted its holdings in shares of Pfizer by 9.6% during the 2nd quarter. Perennial Investment Advisors LLC now owns 15,549 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 1,358 shares during the period. Finally, Lumbard & Kellner LLC boosted its holdings in Pfizer by 8.0% during the second quarter. Lumbard & Kellner LLC now owns 113,901 shares of the biopharmaceutical company’s stock valued at $3,187,000 after purchasing an additional 8,454 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

Shares of PFE stock opened at $26.25 on Thursday. The firm has a market capitalization of $148.76 billion, a price-to-earnings ratio of 35.47, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average of $26.13 and a 200-day moving average of $28.03.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.55%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is 227.03%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Citigroup initiated coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Guggenheim cut their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.